KALA News and Press, Kala Pharmaceuticals Inc. From 06/23/22

Today, we take our first look at ocular focused biotech IVERIC bio, Inc. The stock has seen some insider buying here in June and its primary asset Zumira seems on the path to commercialization. An investment analysis follows in the paragraphs below. For further details see: ...

ARLINGTON, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the...

Kala Pharmaceuticals (KALA) lost ~20% of its value after H.C. Wainwright Analyst Yi Chen lowered the company's price target to $4 from $5. The analyst maintained a Buy rating on the shares. The move comes after KALA entered into a definitive pact to sell its commercial portfoli...

Penny stocks are shares of companies that trade for less than $5. While some people may have their own definitions, this is generally considered the standard. Whatever the case, the goals are the same: make money and repeat the process. One of the most exciting things about finding chea...

Kala Pharmaceuticals (NASDAQ:KALA) has entered into a definitive pact to sell its commercial portfolio and related intellectual property assets to Alcon, which includes EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease, and INVELTYS for the treatment ...

--Kala Will Receive $60 Million in Upfront Payment; Eligible to Receive Additional Sales-Based Milestone Payments-- --Kala Will Focus Resources on Phase 2/3 Trial of KPI-012 for Orphan Disease Persistent Corneal Epithelial Defect-- ARLINGTON, Mass., May 23, 2022 (GLOBE NEWSWIR...

Kala Pharma (NASDAQ:KALA +7.1%) on Monday posted lower-than-expected Q1 revenue, hurt by lower sales of eye treatment, Inveltys. The company reported quarterly net product revenues of $1.4M, consisting of $1M of net revenue from Eysuvis sales and $0.4 million of net revenue from Inveltys...

Kala Pharmaceuticals, Inc. (KALA) Q1 2022 Results Earnings Conference Call May 16, 2022, 08:00 AM ET Company Participants Jill Steier - Executive Director, Investor Relations and Corporate Communications Mark Iwicki - Chairman and Chief Executive Officer Todd Bazemore - President and Chief Op...

Kala Pharmaceuticals press release (NASDAQ:KALA): Q1 GAAP EPS of -$0.45 misses by $0.11. Non-GAAP net loss was $29.5M. Revenue of $1.37M (-58.1% Y/Y) misses by $1.51M. For further details see: Kala Pharmaceuticals GAAP EPS of -$0.45 misses by $0.11, revenue of $1.37M misses by $1.51M

- Expanded Coverage for EYSUVIS® to 92% of Total Commercial Lives and 30% of All Medicare Lives - - Achieved 18% EYSUVIS Prescription Growth in 1Q 2022 - - Presented KPI-012 Phase 1b Clinical Data at ARVO; Initiation of Phase 2/3 Clinical Trial in PCED Expected 4Q 202...